

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation. In particular, this announcement does not constitute and is not an offer to sell or an invitation or a solicitation of any offer to buy or subscribe for any securities in Hong Kong, the United States of America or elsewhere. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities described herein have not been and will not be registered under the U.S. Securities Act. There will be no public offering of securities in the United States of America, the State of Israel or any jurisdiction other than Hong Kong.

Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the United States of America or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

FOSUN 复星

復星國際有限公司
FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 00656)

JOINT ANNOUNCEMENT

**THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF SISRAM MEDICAL LTD
ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED**

PUBLICATION OF THE PROSPECTUS ISSUED BY SISRAM MEDICAL LTD

EXPECTED SIZE OF THE GLOBAL OFFERING AND OFFER PRICE RANGE

The boards of directors of Fosun Pharma and Fosun International announce that in connection with the Proposed Spin-off and Listing, Sisram published its Prospectus on 5 September 2017. The Prospectus is available for viewing and downloading from the websites of Sisram at www.sisram-medical.com and the Hong Kong Stock Exchange at www.hkexnews.hk from 5 September 2017.

Printed copies of the Prospectus may be obtained, free of charge, at designated locations during normal business hours from 9:00 a.m. on Tuesday, 5 September 2017 until 12:00 noon on Friday, 8 September 2017.

As disclosed in the Prospectus, the total number of Sisram Shares to be offered pursuant to the Global Offering will be 110,000,000 (assuming the Over-allotment Option (as defined in the Prospectus) is not exercised), representing approximately 25% of the number of Sisram Shares in issue immediately following the completion of the Capitalization Issue (as defined in the Prospectus) and the Global Offering (assuming the Minimum Offer Price (as defined in the Prospectus)), and 126,500,000 (assuming the Over-allotment Option is exercised in full), representing approximately 27.71% of the number of Sisram Shares in issue immediately following the completion of the Capitalization Issue and the Global Offering (assuming the Minimum Offer Price). The Offer Price for the Sisram Shares in the Global Offering is expected to be not less than HK\$8.88 per Sisram Share and not more than HK\$12.35 per Sisram Share (exclusive of brokerage, SFC transaction levy and Hong Kong Stock Exchange trading fee).

1. Introduction

Fosun Pharma refers to its announcements dated 29 June 2016, 31 August 2016, 6 June 2017, 20 August 2017 and 30 August 2017 (the “**Fosun Pharma Announcements**”) and the circular to its shareholders dated 15 July 2016 relating to the Proposed Spin-off and Listing. The Proposed Spin-off and Listing were approved by Fosun Pharma’s shareholders at the 2016 Second Extraordinary General Meeting held on 31 August 2016.

Fosun International refers to its announcements dated 6 June 2017, 17 August 2017, 20 August 2017 and 30 August 2017 (the “**Fosun International Announcements**”) relating to the Proposed Spin-off and Listing.

Unless the context otherwise requires, terms defined in the Fosun Pharma Announcements and the Fosun International Announcements shall have the same meanings as those used in this announcement.

2. Publication of the Prospectus

In connection with the Proposed Spin-off and Listing, Sisram published the Prospectus on 5 September 2017. The Prospectus contains, among other things, (a) details of the number of Sisram Shares to be offered in the Global Offering, the Offer Price range and other details of the Global Offering and (b) certain business and financial information in relation to Sisram.

The Prospectus is available for viewing and downloading from the websites of Sisram at www.sisram-medical.com and the Hong Kong Stock Exchange at www.hkexnews.hk from 5 September 2017. Printed copies of the Prospectus may be obtained, free of charge, at designated locations specified in (a) the mixed media offer announcement made by Sisram on 4 September 2017, (b) the formal notice issued by Sisram on 5 September 2017 and (c) the Prospectus, during normal business hours from 9:00 a.m. on Tuesday, 5 September 2017 until 12:00 noon on Friday, 8 September 2017.

3. Preferential Offering

In connection with the Preferential Offering, a blue application form has been despatched on 5 September 2017 to each Qualifying Fosun International Shareholder. In addition, Qualifying Fosun International Shareholders will receive a copy of the Prospectus in the manner in which they have elected, or are deemed to have elected, to receive corporate communications under the corporate communications policy of Fosun International. The procedures for applying for Sisram Shares pursuant to the Preferential Offering are set out in the Prospectus.

4. Expected Size of the Global Offering and Offer Price Range

As disclosed in the Prospectus, the total number of Sisram Shares to be offered pursuant to the Global Offering will be 110,000,000 (assuming the Over-allotment Option is not exercised), representing approximately 25% of the number of Sisram Shares in issue immediately following the completion of the Capitalization Issue and the Global Offering (assuming the Minimum Offer Price), and 126,500,000 (assuming the Over-allotment Option is exercised in full), representing approximately 27.71% of the number of Sisram Shares in issue immediately following the completion of the Capitalization Issue and the Global Offering (assuming the Minimum Offer Price).

The Offer Price for the Sisram Shares in the Global Offering is expected to be not less than HK\$8.88 per Sisram Share and not more than HK\$12.35 per Sisram Share (exclusive of brokerage, SFC transaction levy and Hong Kong Stock Exchange trading fee).

On the basis of the number of Sisram Shares to be offered pursuant to the Global Offering and the expected Offer Price range as stated above, if the Global Offering proceeds:

- (a) the market capitalization of Sisram will be between approximately HK\$3,907.2 million and approximately HK\$4,986.2 million (assuming the Over-allotment Option is not exercised) and between approximately HK\$4,053.7 million and approximately HK\$5,190.0 million (assuming the Over-allotment Option is exercised in full);
- (b) the size of the Global Offering will be between approximately HK\$976.8 million and approximately HK\$1,358.5 million (assuming the Over-allotment Option is not exercised) and between approximately HK\$1,123.3 million and approximately HK\$1,562.3 million (assuming the Over-allotment Option is exercised in full);
- (c) Fosun International (through its shareholding interest in Fosun Pharma) and Fosun Pharma (through its wholly-owned subsidiaries), will indirectly hold approximately 52.96% of the Sisram Shares (assuming the Minimum Offer Price and before any exercise of the Over-allotment Option) and approximately 51.05% of the Sisram Shares (assuming the Minimum Offer Price and the full exercise of the Over-allotment Option) immediately following the completion of the Capitalization Issue and the Global Offering.

5. Termination of the Sisram Share Option Scheme

Fosun Pharma refers to its announcements dated 26 August 2014 and 23 April 2015 and the circular to its shareholders dated 12 May 2015, relating to the adoption by Sisram of the Share Option Scheme (the “**Sisram Share Option Scheme**”). The adoption of the Sisram Share Option Scheme was approved by Fosun Pharma’s shareholders at the annual general meeting of Fosun Pharma held on 29 June 2015.

Fosun International refers to its announcements dated 26 August 2014 and 23 April 2015 and the circular to its shareholders dated 24 April 2015, relating to the adoption of the Sisram Share Option Scheme. The adoption of the Sisram Share Option Scheme was approved by Fosun International’s shareholders at the annual general meeting of Fosun International held on 28 May 2015.

As at the date of this announcement, Sisram has not granted any option pursuant to the Sisram Share Option Scheme. On 30 August 2017, the board of directors of Sisram resolved to terminate the Sisram Share Option Scheme, subject to the completion of the Global Offering of Sisram Shares.

6. General

In connection with the Global Offering, the price of the Sisram Shares may be stabilized in accordance with the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). Details of any intended stabilization and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) are contained in the Prospectus.

The Global Offering (including the Preferential Offering) is subject to, among other things, (a) the Offer Price being agreed between the joint global coordinators of the Global Offering (the “**Underwriters**”), the Selling Shareholder (as defined in the Prospectus) and Sisram on or about Monday, 11 September 2017 and, in any event, no later than Monday, 18 September 2017 and (b) the obligations of the Underwriters under (i) the underwriting agreement in relation to the Hong Kong Public Offering entered into by, among others, Sisram and the underwriters of the Hong Kong Public Offering on 4 September 2017 (the “**Hong Kong Underwriting Agreement**”) and (ii) the underwriting agreement in relation to the international offering of Sisram Shares (the “**International Offering**”) to be entered into by, among others, Sisram and the underwriters of the International Offering (the “**International Underwriting Agreement**”) becoming unconditional and not having been terminated in accordance with the respective terms of the Hong Kong Underwriting Agreement and the International Underwriting Agreement.

Accordingly, shareholders and potential investors of Fosun Pharma and/or Fosun International should be aware that there is no assurance that the Proposed Spin-off and Listing (including the Preferential Offering) will proceed. Shareholders and potential investors of Fosun Pharma and/or Fosun International should exercise caution when dealing in or investing in the securities of Fosun Pharma and/or Fosun International. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.

This announcement is not intended to, and does not, constitute an offer to sell or a solicitation of an offer to subscribe for or purchase any Sisram Shares in connection with the Global Offering or otherwise. Any such offer or solicitation is made solely through the Prospectus or other offering documents that may be issued in compliance with applicable laws and any decision to subscribe for or purchase Sisram Shares in connection with the Global Offering or otherwise should be made solely on the basis of the information contained in the Prospectus and such other offering documents. No action has been or will be taken in any jurisdiction (other than in Hong Kong) that would permit a public offering of the Sisram Shares to be offered in the Global Offering in any jurisdiction where action for that purpose is required, including, but not limited to, the United States of America.

Further announcements will be made by Fosun Pharma and Fosun International in respect of the Proposed Spin-off and Listing as and when appropriate.

By order of the board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

By order of the board
Fosun International Limited
Guo Guangchang
Chairman

5 September 2017

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetang, Mr. Wang Can, Ms. Kang Lan and Mr. Gong Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.

* For identification purposes only